

Index

A

- A-7,96,260, 56
- A-8,36,339, 56
- A23187, 10, 14
- ABC-tricyclic benzopyrans, 53
- abhd4, 19, 278
- abhd6, 14
- abhd12, 10, 14
- Abuse potential, 315, 316
- Acyl amino acid conjugates, 54
- N*-Acylethanolamine acid amidase (NAAA), 22
 - inhibitors
 - N*-(cyclohexylcarbonyl)pentadecylamine (CCP), 104
- N*-Acylethanolamines (NAEs), 67
- 2-Acylglycerol, 7
- N*-Acylphosphatidylethanolamines (NAPEs), 10, 14–19, 25, 278
- Adenylyl cyclase, 43, 49–50, 53, 55
- Adiponectin, 377, 379–382
- Adipose tissue, 376–377, 380
- Adrenal, 291, 294, 296
- AEA. *See* Anandamide (AEA)
- Affinity, 40, 41, 48, 53–55
- 2-AG. *See* 2-Arachidonoylglycerol (2-AG)
- Agonism, 42, 43, 51–53, 55
- Agonist-induced trafficking, 42
- Alcohol, 310, 311, 314, 321, 327, 329–330, 334
- Alcoholism, 330
- Alcohol-preferring Marchigian Sardinian, 330
- Allosteric modulators, 56–58
- [¹²³I]AM281, 407
- AM40, 319–321, 324, 330
- AM251, 5, 55, 122, 144, 146, 148, 149, 151, 152, 156–158, 161, 165
- AM281, 55
- AM404, 99, 147, 164
- AM630, 53, 56
- AM1172, 99
- AM1241, 53, 56
- AM4113, 55
- Aminoalkylindoles, 54
 - CP55940, 91
 - WIN55212-2, 91
- AMP-activated protein kinase (AMPK), 248, 376, 377
- Amphetamine, 327, 331, 333–334
- Amphibians, 186–189
 - frogs, 189
 - roughskin newt, 186–189
- Amygdala, 68, 72, 74, 147, 150, 154, 290, 293, 296–302
- Anandamide (AEA), 5, 6, 13–27, 39, 42, 54, 57, 67, 72, 73, 257–269, 312, 313, 318–319, 321, 323–326, 328–331, 333, 334, 348, 375, 378, 379, 391–394
 - transport, 99–100
- Anorectic, 240, 242, 243, 246, 248
- Anorexia nervosa (AN), 379
- Antagonism, 390

- Anticipation, 234, 236, 238–241, 244, 247
 Appetitive, 237, 241–245, 247, 249
N-Arachidonylethanolamine. *See*
 Anandamide (AEA)
 2-Arachidonoylglycerol (2-AG), 6, 9–14,
 22–27, 54, 67–69, 71–74, 77–81, 257–
 260, 262, 312, 313, 319, 325, 329, 333,
 334, 351, 352, 358, 359, 361, 364, 375,
 378, 379
N-Arachidonoylglycine, 20, 25
 Arthritis, 281–283
 Attention-deficit/hyperactivity disorder
 (ADHD), 333
 Autotaxin, 12
 Aversive effects, 317, 322, 323
 Axon guidance, 126
 Axon terminals, 67, 69, 72, 75, 77–81
- B**
 Basal ganglia, 401, 407, 408
 β -cells, 378
 BDNF, 50, 51
 Behavioural experiments, 114, 129–131
 Behavioural sensitization, 327, 332, 333
 Biased agonism, 42
 Binding kinetics, 42
 Binge-eating disorder (BED), 379
 Birds, 189–193
 budgerigar, 190
 pigeon, 189–190
 zebra finch, 190–193
 B_{max} , 40
 Bone metabolism, 283
 Brainstem, 67, 71, 72, 76
 Break-point, 242, 243, 247
 Breeding scheme, 129–131
 Bulimia nervosa (BN), 379
 Buprenorphine, 335
- C**
 Cannabidiol, 390, 391
 Cannabinoid, 348, 349, 360, 361, 363
 classical, 90
 non-classical, 90–91
 Cannabinoid receptor
 brain-type (CB₁), 257
 spleen-type (CB₂), 257
 Cannabinoid receptor interacting protein 1a
 (CRIP1a), 46
 Cannabinoid receptor type 1 (CB₁), 311,
 375–380, 382, 383
 agonists, 92
 allosteric modulators, 94–95
 antagonists, 92–94
 antibody, 70
 inverse agonists, 92–94
 knockout mouse, 379
 NESS0327, 94
 receptor knock-out mice, 122
 receptors, 67, 69–80, 349–364, 375–383,
 389–391, 394
 rimonabant, 92–94
 Cannabinoid receptor type 2 (CB₂), 76
 agonists, 95–96
 antagonists, 96–97
 HU308, 95
 Cannabis, 315, 326, 327, 331, 334, 348, 349,
 354, 357–358, 361, 388–390, 392–394
 Cannabis dependence, 315, 334
Cannabis sativa, 357, 402, 403, 409
 Carrageenan, 279, 281
 Cartwheel interneuron, 156
 CB₁R-interacting protein (CRIP-1a), 165
 Cerebellum, 71–73, 76, 79, 80
 climbing fiber, 149, 150
 parallel fiber, 144, 149–151, 154
 Cerebrospinal fluid (CSF) alterations, 391
 Cheng–Prusoff equation, 41
 Cholecystokinin (CCK), 74, 142,
 157–159, 161
 Cholinergic neurons, 76
 [¹¹C]-MePpP, 73
 CNR2, 45, 46
 CNR1 gene, 44–45, 330, 407
 CNR1 polymorphisms, 44–45
 CNR2 polymorphisms, 46
 CNS, 407
 Cocaine, 150, 312–319, 321, 327, 331–334
 Coincidence detector, 145, 163
 Compensatory mechanisms, 117
 Competition experiments, 69
 Complete Freund's adjuvant (CFA), 281
 Conditional mutagenesis, 117
 Conditional mutants, 124–129, 131, 133

- Conditioned place preference, 315, 322–323, 328, 332
- Conotoxin, 159
- Constitutive receptor activity, 51–53
- Consummatory, 241, 247, 249
- COX. *See* Cyclooxygenase (COX)
- [³H]-CP55940, 70, 73
- CP9,45,598, 55
- CP55,940, 40, 41, 54, 317, 322
- Craving, 232, 236–240, 242, 244, 247, 249
- Cre/loxP system, 117, 118
- Cre recombinase, 117–119, 121, 125, 128–129
- CRIP1a. *See* Cannabinoid receptor interacting protein 1a (CRIP1a)
- Cross-dependency, 328
- Cues, 320–322, 330, 334
- N*-Cyclohexylcarbonylpentadecylamine, 22
- Cyclooxygenase (COX), 23–24
- Cytochrome P450, 24–25
- D**
- DAG. *See* Diacylglycerol (DAG)
- DAG acyltransferases, 8
- DAG kinase, 8
- DAG lipase inhibitors
tetrahydrolipstatin (THL), 104
O-3841, 105
- DALN. *See* Desacetyl-levo-nantradol (DALN)
- Dendritic spine, 311
- Dependence, 310, 311, 315, 317, 325–328, 334
- Depolarization-induced suppression of excitation (DSE), 144, 145, 149, 150, 155–157, 164
- Depolarization-induced suppression of inhibition (DSI), 25, 143–147, 150, 152–155, 158, 159, 162–165
- Depression, 292, 382
- Desacetyl-levo-nantradol (DALN), 53
- Desire, 233, 235, 237, 241, 243, 249
- Detection threshold, 70, 76
- DGL. *See* Diacylglycerol lipase (DGL)
- Diacylglycerol (DAG), 6, 8–10, 12
- Diacylglycerol lipase (DGL), 6, 8–11, 69, 73, 77, 79–81
DGL α , 165
- 1,5-Diarylpyrazoles, 55
- Discrimination, 315, 323, 324
- D2-like dopamine receptor, 408
- Dopamine, 70, 72, 142, 147, 150, 244, 246, 401, 402, 404, 408
- Dopamine transporter (DAT), 331, 332
- Dorsal cochlear nucleus, 156
- Dorsal horn neurones, 279, 281
- Drug addiction, 310–335
- Drug-seeking, 310, 313–316, 319–321, 327
- Drug-taking, 315, 318, 320, 321
- DRY motif, 48
- E**
- Eating, 232–240, 242–249
- Ectopic Cre recombinase expression, 128
- Efficacy, 42, 43, 52–54, 56, 58
- Eicosanoids, 53, 54
anandamide (AEA), 91
2-arachidonoylglycerol (2-AG), 91
- Embryonic stem cells, 114–116, 124
- Embryo transport, 263–266
- Endocannabinoid (EC), 375–379, 382, 383, 389–394
- Endocannabinoid system (ECS), 66–70, 72, 73, 79, 80, 348–364
- Endocannabinoid transporter, 143, 144
- Endorphins, 246, 280
- Endovanilloid, 166
- Energy balance, 233, 237, 249
- Energy expenditure, 380, 382
- EPSP-spike (E-S) potentiation, 148
- Excitotoxicity, 75
- Experimental autoimmune encephalomyelitis (EAE), 127, 128
- Extinction, 205, 209–224
- F**
- FAAH. *See* Fatty acid amide hydrolase (FAAH)
- FAAH-2, 21, 114, 123
- Fatty acid amide hydrolase (FAAH), 10, 12, 13, 20–24, 27, 73, 150, 166, 257–260, 264, 266, 267, 278, 280–283, 313, 319,

- 323, 324, 330, 331, 335, 351–354, 359, 361, 363, 364
 inhibitors
 KDS-4103, 101
 methyl arachidonyl fluorophosphonate (MAFP), 100
 PF-750, 102
 phenyl-methylsulphonyl fluoride (PMSF), 100
 URB597, 101
 Fish, 184–186
 goldfish, 184–186
 puffer fish, 184
 Fixed-ratio schedule, 316–321, 334
 Food-seeking, 249
 Forced swim test (FST), 128, 133
 Formalin, 279
 Functional selectivity, 42, 43, 58
- G**
 GABA, 67, 70, 72, 74, 81
 GABAergic, 244
 interneurons, 74, 75, 79
 medium spiny neurons, 75
 GASP1, 46
 GDE1, 18, 19, 278
 Gene targeting technology, 114–116, 120, 122–124
 Genetic background, 129, 130
 Germ line deletion, 129
 Ghrelin, 248
 GIRK. *See* G-protein-coupled inwardly rectifying potassium channels (GIRK)
 Globus pallidus, 71, 72
 Glutamate, 67, 70, 72, 81
 GPCRs. *See* G-protein-coupled receptors (GPCRs)
 GPR18, 25
 GPR55, 11, 39, 57, 97
 GPR119, 20, 21
 G-protein-coupled inwardly rectifying potassium channels (GIRK), 51
 G-protein-coupled receptors (GPCRs), 38–39, 41, 42, 44, 46, 48–51, 53
 GTP, 39, 40, 42
 GTP γ S, 41–44, 53, 152
 GTP γ S Binding, 41–44
- H**
 HDL cholesterol, 381, 382
 Hedonic, 232, 236, 237, 241, 245–247, 249
 Hemopressin, 55
 Heterotrimeric G, 39
 Hindbrain, 240
 Hippocampus, 71, 72, 77, 80, 145, 148–149, 152–154, 156, 158, 160, 161
 Homeostasis, 232–237
 Homer, 80, 81
 Homologous recombination, 114, 115, 121, 122, 124
 Hunger, 232, 235, 237, 243, 244, 247–249
 Hyperphagia, 238–246, 248
 Hypothalamic neuropeptides, 375
 Hypothalamus, 72, 74, 239, 248, 375, 376
- I**
 Immunogold staining, 79
 Implantation, 256, 261, 264, 266–268
 Incentive, 236, 237, 241–245, 247
 Inflammatory pain, 281, 282
 Ingestion, 232–234, 241, 246
 Inhibitory long-term depression (iLTD), 142, 143, 147–155, 162, 163, 166
 Initial prodromal states, 393
 Inositol-1,4,5-trisphosphate, 9
 Insulin, 377–382
 Interoceptive effects, 324
 Intrinsic efficacy, 42
 Inverse agonism, 51–53, 55
 Inverse agonists, 132
 Invertebrates, 174–184
 ants, 174–176
 hydra, 176–177
 leech, 179–180
 planarian, 177–179
 sea squirt (*Ciona intestinalis*), 182–184
 sea urchin, 181–182
 Ionomycin, 10, 12–14, 25

J

JNJ1661010, 21
 JTE-907, 56
 JWH-133, 56

K

K_D , 40, 41
 Knockout mouse, 68, 115, 117, 120, 124,
 126, 129–132

L

L-7,68,242, 56
 Learning and Memory, 202–225
 Leptin, 236
 Liking, 237, 241, 245–246
 Lipoxygenase (LOX), 24
 Littermate control, 128, 130
 Long-term depression (LTD), 78, 79, 142,
 143, 145, 147–149, 151–156, 163, 166,
 332–334
 Long-term potentiation (LTP), 147–150,
 153–156, 163, 166
 LOX. *See* Lipoxygenase (LOX)
 LPI. *See* Lysophosphatidylinositol (LPI)
 LPLC. *See* Lysophospholipase C (LPLC)
 LPLD. *See* Lysophospholipase D (LPLD)
 LY3,20,135, 55
 Lysophosphatidic acid, 12
 Lysophosphatidylinositol (LPI), 10, 57
 Lysophospholipase C (LPLC), 11
 Lysophospholipase D (LPLD), 11, 12,
 18, 19

M

Macaca mulatta, 316
 MAFP. *See*
 Methylerachidonylfluorophosphonate
 (MAFP)
 MAP Kinases, 50
 Marijuana, 314, 315, 318, 333, 334, 348,
 375, 402–404, 409
 Meal, 233–235, 239, 242, 243, 245, 247,
 248
 Medium spiny cells, 147, 152
 Melanin-concentrating hormone (MCH),
 248

Mesolimbic, 244, 247
 Metabotropic glutamate receptor (mGluR)
 mGluR1, 146, 147, 150, 166
 mGluR5, 80, 81, 148, 166
 Metaplasticity, 163
 Methamphetamine, 314, 333–334
 Methanandamide, 318–319, 321,
 324, 334
 Methylerachidonylfluorophosphonate
 (MAFP), 13, 14, 19, 22
 Methylendioxyamphetamine
 (MDMA), 333–334
 Methylphenidate, 331–333
 MGL. *See* Monoacylglycerol lipase
 (MGL)
 Midbrain, 76, 80
 Miniature inhibitory post-synaptic
 currents (mIPSCs),
 143, 153
 Mitochondriogenesis, 380
 Mitogen-activated protein kinases, 50
 MK-0364. *See* Taranabant
 Model, 205, 206, 209, 218, 222, 223
 Molecular architecture, 67, 80, 81
 Molecular neuroanatomy, 66–68, 70
 Monoacylglycerol lipase (MGL), 10, 13, 14,
 22, 23, 73, 79–81, 166, 278
 inhibitors
N-arachidonylmaleimide (NAM), 103
 methyl arachidonyl fluorophosphonate
 (MAFP), 102
 phenyl-methylsulphonyl fluoride
 (PMSF), 102
 URB602, 103
 Morphine, 312, 321, 323, 326–329
 Motivation, 232–249
 Motor tics, 404
 Mu-opioid, 323, 328

N

NAAA. *See* *N*-Acylethanolamine acid
 amidase (NAAA)
 NAEs. *See* *N*-Acylethanolamines (NAEs)
 Naloxone, 246, 247, 322, 328, 329
 Naltrexone, 318, 321, 329, 335
 NAPE-PLD, 10, 16–19, 25
 NAPEPLD-deficient mice, 123

- NAPEs. *See*
N-Acylphosphatidylethanolamines
 (NAPEs)
- Natural products, 89–91
- Neocortex, 71, 72, 74, 77, 150, 158, 161
- Neuroleptics (NL), 401–404, 409
- Neuropathic pain, 279–281
- Neuropeptide Y (NPY), 248
- Neutral antagonists, 53
- Nicotine, 311, 312, 314, 315, 321, 324, 325,
 327, 330–331, 334
- Nitric oxide (NO) synthase, 154, 155
- Noladin ether, 54
- Non-classical cannabinoids, 53, 54
- Nucleus accumbens (NAC), 147, 148, 152,
 160, 239, 244, 247, 375
- Null mutant, 120–124, 126
- O**
- Obesity, 232–238, 240, 249, 374–383
- Obesogenic, 236
- Obsessive compulsive behaviour (OCB),
 401–406, 409
- Occlusion, 206, 207
- ODA. *See* Oleamide (ODA)
- OEA. *See* *N*-Oleoylethanolamine (OEA)
- OL135, 21
- Oleamide (ODA), 20, 21
- N*-Oleoylethanolamine (OEA), 17, 18,
 20–22, 25
- OMDM169, 13
- On-demand activation, 73
- On-demand hypothesis, 162
- Opioid antagonists, 321, 322, 328
- Opioids, 241, 246–247, 318, 321–323, 326,
 328–329, 335
- Orexigen, 239–240, 246–248
- Orosensory, 240, 241, 246
- Orthosteric, 56, 58
- Osteoarthritis (OA), 281, 282
- Osteoblasts, 283
- Osteocytes, 283
- Overconsumption, 232, 237, 239, 240, 249
- Oxytocin, 142, 161
- P**
- Palatability, 235, 238–243, 245–247
- N*-Palmitoylethanolamine (PEA), 5, 17–22,
 25, 26
- Parallel fibers, 72, 75, 79
- Paraventricular, 161, 162
- Paraventricular nucleus of the hypothalamus
 (PVN), 290, 291, 293–297, 299–301
- Parvalbumin (PV), 158
- Pathophysiology, 289
- PE. *See* Phosphatidylethanolamine (PE)
- PEA. *See* *N*-Palmitoylethanolamine (PEA)
- Periaqueductal gray nucleus, 72
- Perisynaptic signaling machinery, 80
- Peroxisome proliferator-activating receptor-
 γ (PPAR- γ), 376, 377, 381
- PGK-Neo resistance cassette, 120
- PGK-Neo selection cassette, 121, 124
- Phosphatidic acid, 8, 11, 12, 16
- Phosphatidylethanolamine (PE), 14, 15, 17
- Phosphatidylinositol-4,5-bisphosphate
 (PIP₂), 9
- Phospholipase A1 (PLA₁), 10–12, 17
- Phospholipase C (PLC), 6, 7, 9–11, 16, 18,
 19, 144, 147, 148, 150, 156
- Phospholipase D (PLD), 10, 11, 14, 16–19,
 25
- Physical, 310, 317, 325–328
- PIP₂. *See* Phosphatidylinositol-4,5-
 bisphosphate (PIP₂)
- PLA₁. *See* Phospholipase A1 (PLA₁)
- PLC. *See* Phospholipase C (PLC)
- PLD. *See* Phospholipase D (PLD)
- Pleasure, 236, 237, 241, 247, 249
- Polyamines, 17
- Post-mortem analyses, 390–391
- Postsynaptic density, 77–81
- Post-traumatic stress disorder (PTSD), 292,
 352, 364
- Potency, 42
- PPAR α , 24, 97
- Preabsorption tests, 69
- Prefrontal cortex, 290, 293, 295, 297, 298,
 300
- Preimplantation embryo development,
 261–263, 267
- Presynaptic, 77–79, 81
- Priming, 145, 163
- Pro-opiomelanocortin (POMC), 161
- Propranolol, 12
- Protean agonism, 52
- Protein kinase A (PKA), 149, 150, 153–155
- Protein kinase C, 7, 8
- Proteins, 38–40, 42, 44, 46, 47, 50, 51

Psychostimulants, 311, 315, 331–334
PTPN22, 18–20
(PLC)-PTPN22, 278
Purkinje cells, 76, 143, 145, 146, 149, 157

R

Radioligand binding, 40–42, 68, 74, 75
Rats, 312, 313, 317, 320–332, 334
Receptor tyrosine kinases (RTKs),
50, 51
Reinforcement, 311, 316, 317, 324
Reinforcing effects, 311, 312, 315,
317–319, 321, 325, 332–334
Reinstatement, 313, 314, 317, 321–323,
329, 331, 332, 334
Relapse, 313–314, 317, 319–321, 328–330,
334, 335
Retrograde messenger, 67, 80
Reward, 236, 240–247
Reward circuit, 311, 312, 316
Rewarding effects, 311, 312, 322, 323,
328–330
RHC80267, 10
Rheumatoid arthritis (RA), 281, 282
RIM1 α , 153–155
Rimonabant, 5, 122, 128, 132, 133, 144,
147, 148, 157, 238–248, 313, 314, 318,
321, 322, 324, 326, 328–335,
375–378, 380–382
Rimonabant (SR1,41,716A), 55
Rimonabant-precipitated withdrawal,
328
RTKs. *See* Receptor tyrosine kinases
(RTKs)
Ryanodine, 148, 150

S

Saimiri sciureus, 316
Sample size, 129
Satiation, 233
Satiety, 232, 233, 236, 237
Satisfaction, 233, 236, 237, 249
SCH2,26,336, 56
Schizophrenia, 388–394
SEA. *See* *N*-Stearoylethanolamine (SEA)
Second-order schedule, 320–322, 329
Seizure, febrile seizure, 165
Self-administration, 312, 313, 315–323,
328–332, 334

Sham-feeding, 241, 243, 245
SHIP1, 18–20
Single nucleotide polymorphisms (SNPs),
45, 46
SLV-319, 55
SNPs. *See* Single nucleotide polymorphisms
(SNPs)
Spare receptors, 42
SPECT, 407
Spinal cord, 72, 77, 80
Spontaneous withdrawal, 327
SR1,44,528, 50, 53, 56
N-Stearoylethanolamine (SEA), 17, 20
Steatosis, 377, 378
Stimulus, 320, 321, 323, 324, 331
Stress, 124, 128
Striatum, 145, 147–149, 152, 166
Substantia nigra pars reticulata, 71, 72
Supraoptic nuclei, 161
Surinabant, 242, 248
Synaptic depression, 78
Synaptic neurotransmission, 67, 70, 72
Synaptogenesis, 126

T

Taranabant, 55, 94, 382
Taste reactivity, 245–247
Tetrad, 315
 Δ^9 -Tetrahydrocannabinol (THC),
112, 121, 124, 126, 127, 159, 312,
314–331, 333, 348, 375, 388,
403–409
Tetrahydrolipstatin (THL), 10, 13
Thermogenesis, 380
Thiazolylidine compounds, 56
THL. *See* Tetrahydrolipstatin (THL)
Tics, 401–405, 407–409
Timing dependent LTD (tLTD),
155
Tobacco, 331
Tolerance, 310, 311, 315, 325–327
Tourette's syndrome (TS), 400–410
Transactivation, 50–51
Transient receptor potential vanilloid
type 1 (TRPV-1), 24, 26, 91, 97, 99, 101,
144, 166
Triacylglycerols, 8, 10
Triglycerides, 380–382
TRPA1, 21

TRPM8, 57

TRPV1 knockout mice, 124

U

Unitary inhibitory post-synaptic current
(uIPSC), 159

URB597, 21, 22, 27, 281, 313, 319, 320,
323, 324, 330, 331

URB602, 13

URB754, 13

V

VDM-11, 161, 164

Ventral tegmental area (VTA), 150

Virodhamine, 54

Visfatin, 377

Vocal tic, 400, 403, 404

Voltage-gated calcium channel

L-type, 147

N-type, 143, 145

W

Wanting, 237, 241–245

WIN 55, 212-2, 27, 150–154, 159, 161, 164,
314, 317, 321, 322, 326, 330, 331, 333,
353, 355, 359, 363, 364